Farnesoid X receptor: from medicinal chemistry to clinical applications.

The farnesoid X receptor (FXR) is a bile sensor that acts in coordination with other nuclear receptors to regulate essential steps in bile acid uptake, metabolism and excretion. In addition, FXR is an ancillary receptor involved in lipid and glucose homeostasis. Steroidal and non-steroidal FXR ligands are currently available. Both groups have shown limitations in the preclinical studies regarding absorption, metabolism, specificity of target and intrinsic toxicity. FXR ligands endowed with agonistic activity are under development for the treatment of cholestatic liver diseases, including primary biliary cirrhosis and metabolic disorders linked to insulin resistance. Despite the fact that results from preclinical models are encouraging, targeting FXR holds potential for side effects (i.e., impaired cholesterol disposal and cholestasis). Thus, results from FXR gene-ablated mice and mice administered an FXR antagonist support a role for FXR antagonists or modulators (i.e., FXR agonists that selectively activate specific subsets of FXR target genes in a tissue) or co-regulator-specific manner.

[1]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[2]  M. Downes,et al.  FXR and PXR: Potential therapeutic targets in cholestasis , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  M. Orešič,et al.  Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.

[4]  M. Christian,et al.  Metabolic regulation by the nuclear receptor corepressor RIP140 , 2006, Trends in Endocrinology & Metabolism.

[5]  F. Moy,et al.  The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. , 2006, Endocrinology.

[6]  S. Fiorucci,et al.  The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo , 2006, Molecular Pharmacology.

[7]  K. Houck,et al.  The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.

[8]  J. W. Becker,et al.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation , 2008, Proceedings of the National Academy of Sciences.

[9]  K. Houck,et al.  T0901317 is a dual LXR/FXR agonist. , 2004, Molecular genetics and metabolism.

[10]  S. Mudaliar,et al.  A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY , 2009 .

[11]  G. Bifulco,et al.  The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis , 2011, PloS one.

[12]  D. Hum,et al.  The farnesoid X receptor induces very low density lipoprotein receptor gene expression , 2004, FEBS letters.

[13]  G. Bifulco,et al.  Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. , 2011, Journal of medicinal chemistry.

[14]  J. Boyer,et al.  The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[15]  F. Baldelli,et al.  Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. , 2010, Progress in lipid research.

[16]  E. Distrutti,et al.  Antiatherosclerotic effect of farnesoid X receptor. , 2009, American journal of physiology. Heart and circulatory physiology.

[17]  T. Willson,et al.  Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. , 2004, Journal of medicinal chemistry.

[18]  Marco Migliorati,et al.  Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. , 2011, Biochimica et biophysica acta.

[19]  K. Kostner,et al.  Farnesoid X receptor represses hepatic human APOA gene expression. , 2011, The Journal of clinical investigation.

[20]  R. Evans,et al.  Benefit of farnesoid X receptor inhibition in obstructive cholestasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Boyer,et al.  Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis , 2006, Hepatology.

[22]  Gabriele Costantino,et al.  Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.

[23]  Songwen Zhang,et al.  Abstract 584: A Synthetic Farnesoid X Receptor Agonist Protects Against Diet-Induced Dyslipidemia , 2007 .

[24]  G. Bifulco,et al.  Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis , 2012, PloS one.

[25]  E. Distrutti,et al.  Targeting farnesoid X receptor for liver and metabolic disorders. , 2007, Trends in molecular medicine.

[26]  F. Carrat,et al.  The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. , 2005, Gastroenterology.

[27]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[28]  D. Hum,et al.  Farnesoid X receptor represses hepatic lipase gene expression Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400221-JLR200 , 2004, Journal of Lipid Research.

[29]  Giuseppe Bifulco,et al.  Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. , 2011, Journal of medicinal chemistry.

[30]  Kazuhide Inoue,et al.  The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. , 2008, Journal of pharmacological sciences.

[31]  M. Evans,et al.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice Published, JLR Papers in Press, January 27, 2009. , 2009, Journal of Lipid Research.

[32]  Jasmine Chen,et al.  Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.

[33]  Jasmine Chen,et al.  Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.

[34]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[35]  K. Lindor,et al.  2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID , 2010 .

[36]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[37]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[38]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[39]  S. Fiorucci,et al.  The bile acid sensor FXR regulates insulin transcription and secretion. , 2010, Biochimica et biophysica acta.

[40]  S. Fiorucci,et al.  Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. , 2010, Current medicinal chemistry.

[41]  M. Trauner,et al.  Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. , 2007, Biochimica et biophysica acta.

[42]  F. Pattou,et al.  The nuclear receptor FXR is expressed in pancreatic β‐cells and protects human islets from lipotoxicity , 2010, FEBS letters.

[43]  J. Chiang,et al.  Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.